282 related articles for article (PubMed ID: 16969427)
1. Combined cannabinoid therapy via an oromucosal spray.
Perez J
Drugs Today (Barc); 2006 Aug; 42(8):495-503. PubMed ID: 16969427
[TBL] [Abstract][Full Text] [Related]
2. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.
Robson P
Expert Opin Drug Saf; 2011 Sep; 10(5):675-85. PubMed ID: 21542664
[TBL] [Abstract][Full Text] [Related]
3. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
4. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
5. Cannabis; adverse effects from an oromucosal spray.
Scully C
Br Dent J; 2007 Sep; 203(6):E12; discussion 336-7. PubMed ID: 17703180
[TBL] [Abstract][Full Text] [Related]
6. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
8. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Barnes MP
Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
[TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
Rog DJ; Nurmikko TJ; Friede T; Young CA
Neurology; 2005 Sep; 65(6):812-9. PubMed ID: 16186518
[TBL] [Abstract][Full Text] [Related]
10. [Marihuana and cannobinoids as medicaments].
Tkaczyk M; Florek E; Piekoszewski W
Przegl Lek; 2012; 69(10):1095-7. PubMed ID: 23421098
[TBL] [Abstract][Full Text] [Related]
11. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
Moreno Torres I; Sanchez AJ; Garcia-Merino A
Expert Rev Neurother; 2014 Nov; 14(11):1243-50. PubMed ID: 25331416
[TBL] [Abstract][Full Text] [Related]
13. Sativex for the management of multiple sclerosis symptoms.
Perras C
Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
[TBL] [Abstract][Full Text] [Related]
14. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.
Oreja-Guevara C
Expert Rev Neurother; 2012 Apr; 12(4 Suppl):3-8. PubMed ID: 22509985
[TBL] [Abstract][Full Text] [Related]
16. Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex
Keating GM
Drugs; 2017 Apr; 77(5):563-574. PubMed ID: 28293911
[TBL] [Abstract][Full Text] [Related]
17. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
Fernández O
Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
[TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
Iskedjian M; Bereza B; Gordon A; Piwko C; Einarson TR
Curr Med Res Opin; 2007 Jan; 23(1):17-24. PubMed ID: 17257464
[TBL] [Abstract][Full Text] [Related]
19. Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research.
Schoedel KA; Harrison SJ
Curr Pharm Des; 2012; 18(32):5008-14. PubMed ID: 22716155
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
Paolicelli D; Direnzo V; Manni A; D'Onghia M; Tortorella C; Zoccolella S; Di Lecce V; Iaffaldano A; Trojano M
J Clin Pharmacol; 2016 Jul; 56(7):845-51. PubMed ID: 26608223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]